

William Duddy

List of Publications by Year in descending order

Source: [//exaly.com/author-pdf/8253552/publications.pdf](https://exaly.com/author-pdf/8253552/publications.pdf)

Version: 2024-02-01

49
papers

1,285
citations

341340

20
h-index

372325

34
g-index

50
all docs

50
docs citations

50
times ranked

2266
citing authors

#	ARTICLE	IF	CITATIONS
1	Extracellular Vesicles in Amyotrophic Lateral Sclerosis. <i>Life</i> , 2023, 13, 121.	2.5	4
2	HGCA2.0: An RNA-Seq Based Webtool for Gene Coexpression Analysis in Homo sapiens. <i>Cells</i> , 2023, 12, 388.	4.3	2
3	Genome-Wide Gene-Set Analysis Identifies Molecular Mechanisms Associated with ALS. <i>International Journal of Molecular Sciences</i> , 2023, 24, 4021.	4.2	1
4	Serum Neurofilaments in Motor Neuron Disease and Their Utility in Differentiating ALS, PMA and PLS. <i>Life</i> , 2023, 13, 1301.	2.5	3
5	Muscle cells of sporadic amyotrophic lateral sclerosis patients secrete neurotoxic vesicles. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2022, 13, 1385-1402.	7.4	22
6	The Neurotoxicity of Vesicles Secreted by ALS Patient Myotubes Is Specific to Exosome-Like and Not Larger Subtypes. <i>Cells</i> , 2022, 11, 845.	4.3	8
7	The Role of Sphingomyelin and Ceramide in Motor Neuron Diseases. <i>Journal of Personalized Medicine</i> , 2022, 12, 1418.	2.6	11
8	The Cellular and Molecular Signature of ALS in Muscle. <i>Journal of Personalized Medicine</i> , 2022, 12, 1868.	2.6	8
9	Genome-Wide Gene-Set Analysis Approaches in Amyotrophic Lateral Sclerosis. <i>Journal of Personalized Medicine</i> , 2022, 12, 1932.	2.6	2
10	Understanding Neuromuscular Health and Disease: Advances in Genetics, Omics, and Molecular Function. <i>Journal of Personalized Medicine</i> , 2021, 11, 438.	2.6	0
11	eSkip-Finder: a machine learning-based web application and database to identify the optimal sequences of antisense oligonucleotides for exon skipping. <i>Nucleic Acids Research</i> , 2021, 49, W193-W198.	14.0	15
12	Optimized Molecular Interaction Networks for the Study of Skeletal Muscle. <i>Journal of Neuromuscular Diseases</i> , 2021, 8, 1-17.	2.8	0
13	snpQT: flexible, reproducible, and comprehensive quality control and imputation of genomic data. <i>F1000Research</i> , 2021, 10, 567.	1.6	1
14	Arabidopsis Coexpression Tool: a tool for gene coexpression analysis in Arabidopsis thaliana. <i>IScience</i> , 2021, 24, 102848.	4.1	12
15	RIPK3-mediated cell death is involved in DUX4-mediated toxicity in facioscapulohumeral dystrophy. <i>Journal of Cachexia, Sarcopenia and Muscle</i> , 2021, 12, 2079-2090.	7.4	11
16	Exosomes in Ageing and Motor Neurone Disease: Biogenesis, Uptake Mechanisms, Modifications in Disease and Uses in the Development of Biomarkers and Therapeutics. <i>Cells</i> , 2021, 10, 2930.	4.3	23
17	Epidemiology and Survival Trends of Motor Neurone Disease in Northern Ireland from 2015-2019. <i>European Journal of Neurology</i> , 2021, , .	3.6	7
18	A Dystrophin Exon-52 Deleted Miniature Pig Model of Duchenne Muscular Dystrophy and Evaluation of Exon Skipping. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13065.	4.2	12

#	ARTICLE	IF	CITATIONS
19	What Can Machine Learning Approaches in Genomics Tell Us about the Molecular Basis of Amyotrophic Lateral Sclerosis?. <i>Journal of Personalized Medicine</i> , 2020, 10, 247.	2.6	14
20	Molecular and Cellular Mechanisms Affected in ALS. <i>Journal of Personalized Medicine</i> , 2020, 10, 101.	2.6	85
21	MyoMiner: explore gene co-expression in normal and pathological muscle. <i>BMC Medical Genomics</i> , 2020, 13, 67.	1.5	7
22	Optimized method for extraction of exosomes from human primary muscle cells. <i>Skeletal Muscle</i> , 2020, 10, 20.	4.4	38
23	A Systematic Review of Genotype-Phenotype Correlation across Cohorts Having Causal Mutations of Different Genes in ALS. <i>Journal of Personalized Medicine</i> , 2020, 10, 58.	2.6	37
24	Exons 45-55 Skipping Using Mutation-Tailored Cocktails of Antisense Morpholinos in the DMD Gene. <i>Molecular Therapy</i> , 2019, 27, 2005-2017.	8.1	36
25	A Systematic Review of Suggested Molecular Strata, Biomarkers and Their Tissue Sources in ALS. <i>Frontiers in Neurology</i> , 2019, 10, 400.	2.5	58
26	Muscle Gene Sets: a versatile methodological aid to functional genomics in the neuromuscular field. <i>Skeletal Muscle</i> , 2019, 9, 10.	4.4	8
27	Identification of Novel Antisense-Mediated Exon Skipping Targets in DYSF for Therapeutic Treatment of Dysferlinopathy. <i>Molecular Therapy - Nucleic Acids</i> , 2018, 13, 596-604.	5.1	28
28	Personalized Medicine and Molecular Interaction Networks in Amyotrophic Lateral Sclerosis (ALS): Current Knowledge. <i>Journal of Personalized Medicine</i> , 2018, 8, 44.	2.6	13
29	Direct Reprogramming of Human DMD Fibroblasts into Myotubes for In Vitro Evaluation of Antisense-Mediated Exon Skipping and Exons 45-55 Skipping Accompanied by Rescue of Dystrophin Expression. <i>Methods in Molecular Biology</i> , 2018, 1828, 141-150.	0.0	8
30	Antisense PMO cocktails effectively skip dystrophin exons 45-55 in myotubes transdifferentiated from DMD patient fibroblasts. <i>PLoS ONE</i> , 2018, 13, e0197084.	2.5	22
31	Annexin A2 links poor myofiber repair with inflammation and adipogenic replacement of the injured muscle. <i>Human Molecular Genetics</i> , 2017, 26, 1979-1991.	3.0	49
32	Quantitative Antisense Screening and Optimization for Exon 51 Skipping in Duchenne Muscular Dystrophy. <i>Molecular Therapy</i> , 2017, 25, 2561-2572.	8.1	63
33	Skeletal muscle characteristics are preserved in hTERT/cdk4 human myogenic cell lines. <i>Skeletal Muscle</i> , 2016, 6, 43.	4.4	60
34	623. Dystrophin Exon 52-Deleted Pigs as a New Animal Model of Duchenne Muscular Dystrophy: Its Characterization and Potential as a Tool for Developing Exon Skipping Therapy. <i>Molecular Therapy</i> , 2016, 24, S247.	8.1	0
35	Changes in Communication between Muscle Stem Cells and their Environment with Aging. <i>Journal of Neuromuscular Diseases</i> , 2015, 2, 205-217.	2.8	19
36	Muscular dystrophy in the mdx mouse is a severe myopathy compounded by hypotrophy, hypertrophy and hyperplasia. <i>Skeletal Muscle</i> , 2015, 5, 16.	4.4	111

#	ARTICLE	IF	CITATIONS
37	CellWhere: graphical display of interaction networks organized on subcellular localizations. <i>Nucleic Acids Research</i> , 2015, 43, W571-W575.	14.0	23
38	Age-Associated Methylation Suppresses SPRY1 , Leading to a Failure of Re-quiescence and Loss of the Reserve Stem Cell Pool in Elderly Muscle. <i>Cell Reports</i> , 2015, 13, 1172-1182.	6.3	97
39	In Silico Screening Based on Predictive Algorithms as a Design Tool for Exon Skipping Oligonucleotides in Duchenne Muscular Dystrophy. <i>PLoS ONE</i> , 2015, 10, e0120058.	2.5	47
40	Dystrophin deficiency leads to disturbance of LAMP1-vesicle-associated protein secretion. <i>Cellular and Molecular Life Sciences</i> , 2013, 70, 2159-2174.	5.5	55
41	Exon skipping for nonsense mutations in Duchenne muscular dystrophy: too many mutations, too few patients?. <i>Expert Opinion on Biological Therapy</i> , 2012, 12, 1141-1152.	3.2	36
42	Activation of Notch Signaling During <i>Ex Vivo</i> Expansion Maintains Donor Muscle Cell Engraftment. <i>Stem Cells</i> , 2012, 30, 2212-2220.	3.6	49
43	Atmospheric Oxygen Tension Slows Myoblast Proliferation via Mitochondrial Activation. <i>PLoS ONE</i> , 2012, 7, e43853.	2.5	14
44	The isolated muscle fibre as a model of disuse atrophy: Characterization using PhAct, a method to quantify f-actin. <i>Experimental Cell Research</i> , 2011, 317, 1979-1993.	2.6	15
45	Isolated Murine Myofibres Undergo Atrophy Ex Vivo Via Diminution of the Myonuclear Domain. <i>FASEB Journal</i> , 2011, 25, 1051.20.	0.5	0
46	Mimicry by α - and β -turns of the four main types of β -turn in proteins. <i>Protein Science</i> , 2008, 13, 3051-3055.	7.8	66
47	Potential of oligonucleotide-mediated exon-skipping therapy for Duchenne muscular dystrophy. <i>Expert Opinion on Biological Therapy</i> , 2007, 7, 831-842.	3.2	50
48	Recurring main-chain anion-binding motifs in short polypeptides: nests. <i>Acta Crystallographica Section D: Biological Crystallography</i> , 2004, 60, 1935-1942.	2.4	31
49	snpQT: flexible, reproducible, and comprehensive quality control and imputation of genomic data. <i>F1000Research</i> , 0, 10, 567.	1.6	1